EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co-targeting of the protein kinase FAK and MEK in GNAQ-driven uveal melanoma

Simone Lubrano, Rodolfo Daniel Cervantes-Villagrana, Nadia Arang, Adam Officer, Sendi Rafael Adame-Garcia, Gabriela Cuesta-Margolles, Andrew E Aplin, J Silvio Gutkind

Journal of Biological Chemistry · 2025

DOI: 10.1016/j.jbc.2025.110712 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Simone Lubrano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, …. Hauptthemen laut MEDLINE: Melanoma, Uveal Neoplasms, Proto-Oncogene Proteins c-bcl-2, GTP-Binding Protein alpha Subunits, Gq-G11. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, US Department of Defense, Melanoma Research Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uveal melanoma (UVM) is the most common eye cancer in adults, with 50% of patients developing overt metastasis that often proves fatal. The majority of UVM harbor mutations in GNAQ or GNA11, encoding constitutively active Gαq proteins. Combined inhibition of MEK and FAK downstream of Gαq has shown promising effects in UVM cells by inducing apoptotic cell death, but resistance to this strategy can occur in the clinic. Here, we aimed to identify new targets to overcome resistance to MEK + FAK inhibition (FAKi + MEKi). Reverse-phase protein array (RPPA) analysis in UVM cells treated with FAKi + MEKi showed increased levels of pro-apoptotic proteins, such as PUMA and BIM, which promoted cell death. However, we observed an adaptive increase in anti-apoptotic proteins, including BCL2, upon FAK + MEK blockade. We generated UVM cells resistant to FAKi + MEKi by prolonged exposure. Whole-exome sequencing did not reveal relevant acquired mutations; instead, resistant cells exhibit increased BCL2 levels. Moreover, expression of a stable BCL2 mutant confers resistance to both FAKi + MEKi and FAKi+"RAF-MEK clamp" (avutometinib) treatment. Of direct translational relevance, we found that an approved BCL2 inhibitor (venetoclax) displays synergistic efficacy with FAK + MEK blockade and overcomes acquired resistance, including when combined with darovasertib, a dual PKC/PKN inhibitor limiting MEK and FAK signaling that is under clinical evaluation. Our findings suggest that resistance to FAKi + MEKi in UVM cells can be driven by an adaptive upregulation of the anti-apoptotic protein BCL2, and that, in turn, BCL2 inhibitors represent a promising precision-targeted strategy to overcome FAKi + MEKi treatment resistance and improve therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaUveal NeoplasmsProto-Oncogene Proteins c-bcl-2GTP-Binding Protein alpha Subunits, Gq-G11Drug Resistance, NeoplasmProtein Kinase InhibitorsFocal Adhesion Kinase 1HumansUveal MelanomaCell Line, TumorApoptosisAnimalsMAP Kinase Kinase 2

Stichwörter der Autor:innen

BCL2FAKMEKavutometinibdarovasertibresistanceuveal melanomavenetoclax

Substanzen

Proto-Oncogene Proteins c-bcl-2GTP-Binding Protein alpha Subunits, Gq-G11GNAQ protein, humanBCL2 protein, humanProtein Kinase InhibitorsFocal Adhesion Kinase 1PTK2 protein, humanMAP2K2 protein, humanMAP Kinase Kinase 2

Autor:innen und Institutionen

  • Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA; Department of Pharmacy, University of Pisa,…
  • Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA.
  • Moores Cancer Center, University of California San Diego, La Jolla, California, USA.
  • Department of Pharmacology, Physiology and Cancer Biology, Sidney Kimmel Cancer Comprehensive Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA. Electronic address: sgutkind@health.ucsd.ed…

Förderung

  • NCI NIH HHS
  • US Department of Defense
  • Melanoma Research Alliance
  • National Cancer Institute
  • National Institutes of Health
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions
  • Horizon 2020 Framework Programme

Zitieren

APA

Lubrano, S., Cervantes-Villagrana, R. D., Arang, N., Officer, A., Adame-Garcia, S. R., Cuesta-Margolles, G., Aplin, A. E., & Gutkind, J. S. (2025). Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co-targeting of the protein kinase FAK and MEK in GNAQ-driven uveal melanoma. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110712

Vancouver

Lubrano S, Cervantes-Villagrana RD, Arang N, Officer A, Adame-Garcia SR, Cuesta-Margolles G, et al. Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co-targeting of the protein kinase FAK and MEK in GNAQ-driven uveal melanoma. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110712

BibTeX
@article{Lubrano2025,
  author = {Lubrano, Simone and Cervantes-Villagrana, Rodolfo Daniel and Arang, Nadia and Officer, Adam and Adame-Garcia, Sendi Rafael and Cuesta-Margolles, Gabriela and Aplin, Andrew E and Gutkind, J Silvio},
  title = {Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co-targeting of the protein kinase FAK and MEK in GNAQ-driven uveal melanoma},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  doi = {10.1016/j.jbc.2025.110712}
}
Kostenlos starten →